Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc.

CourtDistrict Court, M.D. Florida
DecidedMarch 14, 2023
Docket8:21-cv-00942
StatusUnknown

This text of Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc. (Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc., (M.D. Fla. 2023).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

SHANDONG LUXI PHARMACEUTICAL CO., LTD.,

Plaintiff,

v. Case No: 8:21-cv-942-CEH-AEP

CAMPHOR TECHNOLOGIES, INC.,

Defendant. ___________________________________/

ORDER This matter comes before the Court on the Plaintiff/Counterclaim Defendant Shandong Luxi Pharmaceutical Co., Ltd.’s (“Luxi”) Amended Motion to Dismiss Amended Counterclaims (Doc. 70). In the motion, Luxi requests the Court dismiss Defendant/Counterclaim Plaintiff Camphor Technologies, Inc.’s (“Camphor”) Amended Counterclaims. Camphor responds in opposition. Doc. 72. The Court, having considered the motion and being fully advised in the premises, will grant, in part, Luxi’s Motion to Dismiss Amended Counterclaims. I. BACKGROUND1

1 The following statement of facts is derived from the Amended Counterclaim (Doc. 66 at 12–21), the allegations of which the Court must accept as true in ruling on the instant Motion to Dismiss. Linder v. Portocarrero, 963 F.2d 332, 334 (11th Cir. 1992); Quality Foods de Centro Am., S.A. v. Latin Am. Agribusiness Dev. Corp. S.A., 711 F.2d 989, 994 (11th Cir. 1983). Defendant Camphor is a Florida corporation with its principal place of business in Sarasota, Florida. Doc. 66 at 12, ¶ 1.2 Luxi is a foreign corporation organized under the laws of the People’s Republic of China with its principal place of business in

Shandong, China. Id. at 12, ¶ 2. Luxi initiated this action against Camphor, thereby subjecting itself to the jurisdiction of this Court. Id. at 12–13, ¶ 4; see also Doc. 1. In its Amended Complaint, Luxi asserted claims against Camphor for injunctive relief, breach of contract based on the purchase order, breach of contract based on the exclusivity agreement, conversion, tortious interference with a business relationship,

unjust enrichment, and replevin. Doc. 37. Camphor and its affiliates are users and distributors of active pharmaceutical ingredients (“API”) in the United States and European pharmacopeia markets. Doc. 66 at 13, ¶ 7. One of the APIs that Camphor uses and distributes is Polymyxin B

Sulfate. Id. ¶ 8. On June 24, 2014, Camphor signed its first Executive Agency and Supply Agreement with Luxi. Id. ¶ 9. There have been three Executive Agency and Supply Agreements between Camphor and Luxi. Id. ¶ 10. Pursuant to the Agreements, Camphor added Luxi’s production supply of Polymyxin B Sulfate to its products. Id. ¶ 11. From 2014 through 2019, Camphor and

its affiliates purchased millions of dollars of Polymyxin B Sulfate from Luxi. Id. ¶ 12. On February 26, 2019, Camphor and Luxi entered into the third Exclusive Agency

2 Camphor’s Amended Counterclaim is included in its Answer and Affirmative Defenses. See Doc. 66 at 12–21. Because the Amended Counterclaim, which begins at page 12 of the Answer, numbers the paragraphs beginning again at paragraph numbered one, any paragraph number cited refers to paragraphs contained in the Amended Counterclaim. and Supply Agreement (“the 2019 Agreement”). Id. ¶ 13. Under the 2019 Agreement, Luxi agreed not to sell the Polymyxin B Sulfate to anyone other than Camphor. Id. ¶ 14. Camphor began placing orders in March 2019 pursuant to the 2019 Agreement,

but shortly thereafter Luxi refused to provide the product at the agreed price. Id. ¶¶ 15, 16. Luxi began selling to other purchasers at premium prices while not fulfilling Camphor’s orders. Id. ¶ 17. Additionally, Luxi contacted Camphor’s customers in an effort to secure direct sales, notwithstanding Luxi’s contractual obligations to

Camphor. Id. Camphor notified Luxi of its breach of the 2019 Agreement and demanded that Luxi cease such activities. Id. ¶ 18. Camphor also claims Luxi disclosed confidential information in this litigation by failing to redact the Agreements filed.3 Camphor sues Luxi in a four-count Amended Counterclaim asserting claims for injunction (Count I), breach of contract (Count II), tortious interference with

advantageous business relationships (Count III), and misappropriation of trade secrets (Count IV). Doc. 66. Luxi moves to dismiss the amended counterclaim with prejudice. Doc. 70. Camphor filed a response in opposition. Doc. 72. II. LEGAL STANDARD To survive a motion to dismiss under Rule 12(b)(6), a pleading must include a

“short and plain statement of the claim showing that the pleader is entitled to relief.” Ashcroft v. Iqbal, 556 U.S. 662, 677-78 (2009) (quoting Fed. R. Civ. P. 8(a)(2)). Labels, conclusions and formulaic recitations of the elements of a cause of action are not

3 Redacted versions have now been filed. See Doc. 59-1. sufficient. Id. (citing Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007)). Furthermore, mere naked assertions are not sufficient. Id. A complaint must contain sufficient factual matter, which, if accepted as true, would “state a claim to relief that

is plausible on its face.” Id. (quoting Twombly, 550 U.S. at 570). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. (citation omitted). The court, however, is not bound to accept as true a legal

conclusion stated as a “factual allegation” in the complaint. Id. III. DISCUSSION A. Injunction Count I of the Amended Counterclaim seeks to sue Luxi for “injunction.” Camphor alleges that Luxi has breached the 2019 Agreement by producing,

marketing, attempting to sell and selling the Polymyxin B Sulfate product to other entities during the term of the 2019 Agreement. Doc. 66 ¶ 24. Camphor further alleges that Luxi breached the exclusivity provisions of the 2019 Agreement in improperly disclosing and using confidential information under the Agreement. Id. ¶¶ 25–28. Camphor demands preliminary and permanent injunctive relief.

In its motion to dismiss, Luxi argues this count is due to be dismissed because the Court already denied Camphor’s motion for preliminary injunction for failing to demonstrate irreparable harm. Doc. 70 at 5–6. This count fails for the fundamental reason that an injunction is not a cause of action, but a remedy. See Pierson v. Orlando Reg’l Healthcare Sys., Inc., 619 F. Supp. 2d 1260, 1288–89 (M.D. Fla. 2009), aff’d, 451 F. App’x 862 (11th Cir. 2012) (collecting

cases). The Eleventh Circuit has made clear that “any motion or suit for either a preliminary or permanent injunction must be based upon a cause of action. . . . There is no such thing as a suit for a traditional injunction in the abstract. For a traditional injunction to be even theoretically available, a plaintiff must be able to articulate a basis for relief that would withstand scrutiny under Fed. R. Civ. P. 12(b)(6) (failure to

state a claim).” Alabama v. U.S. Army Corps of Eng’rs, 424 F.3d 1117, 1127 (11th Cir. 2005) (citation and internal quotation marks omitted); see also Blue Water Innovations, LLC v. Fettig, 18-60671-CIV, 2019 WL 1904589, at *2 (S.D. Fla. Mar.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

American Red Cross v. Palm Beach Blood Bank, Inc.
143 F.3d 1407 (Eleventh Circuit, 1998)
State of Alabama v. U.S. Army Corps of Engineers
424 F.3d 1117 (Eleventh Circuit, 2005)
Vega v. T-MOBILE USA, INC.
564 F.3d 1256 (Eleventh Circuit, 2009)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Tamiami Trail Tours, Inc. v. Cotton
463 So. 2d 1126 (Supreme Court of Florida, 1985)
Ethan Allen, Inc. v. Georgetown Manor
647 So. 2d 812 (Supreme Court of Florida, 1994)
East Colonial Refuse Service, Inc. v. Velocci
416 So. 2d 1276 (District Court of Appeal of Florida, 1982)
Friedman v. New York Life Ins. Co.
985 So. 2d 56 (District Court of Appeal of Florida, 2008)
Rollins, Inc. v. Butland
951 So. 2d 860 (District Court of Appeal of Florida, 2006)
FERGUSON TRANS. v. North American Van Lines, Inc.
687 So. 2d 821 (Supreme Court of Florida, 1996)
Pierson v. Orlando Regional Healthcare Systems, Inc.
619 F. Supp. 2d 1260 (M.D. Florida, 2009)
Swope Rodante, P.A. v. Harmon
85 So. 3d 508 (District Court of Appeal of Florida, 2012)
Del Monte Fresh Produce Co. v. Dole Food Co., Inc.
136 F. Supp. 2d 1271 (S.D. Florida, 2001)
Linder v. Portocarrero
963 F.2d 332 (Eleventh Circuit, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/shandong-luxi-pharmaceutical-co-ltd-v-camphor-technologies-inc-flmd-2023.